Bibliography
- Norgren L, Hiatt WR, Dormany JA, et al. Inter-Society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007;4S:S1-68
- The STILE Investigators. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. The STILE trial. Ann Surg 1994;220:251-66
- Ouriel K, Shortell CK, Deweese JA, et al. A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. J Vasc Surg 1994;19:1021-30
- Ouriel K, Veith FJ, Sasahara AA. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators. N Engl J Med 1998;338:1105-11
- Berridge DC, Gregson RHS, Hopkinson BR, Makin GS. Randomized trial of intra-arterial recombinant tissue plasminogen activator, intravenous plasminogen activator and intraarterial streptokinase in peripheral arterial thrombolysis. Br J Surg 1991;78:988-95
- Braithwaite BD, Buckenham TM, Galland RB, et al. Prospective randomized trial of high-dose bolus versus low-dose tissue plasminogen activator infusion in the management of acute limb ischaemia. Thrombolysis Study Group. Br J Surg 1997;84(5):646-50
- Graor R, Risius B, Lucas FV, et al. Thrombolysis with recombinant human tissue-type plasminogen activator in patients with peripheral arterial disease. Circulation 1986;74(Suppl 1):1-15
- Verstraete M, Hess H, Mahler F, et al. Femoro-popliteal artery thrombolysis with intra-arterial infusion of recombinant tissue-type plasminogen activator – Report of a pilot trial. Eur J Vasc Surg 1988;2:155-9
- Earnshaw JJ, Westhy JC, Gregson RHS, et al. Local thrombolytic therapy of peripheral arterial ischaemia with tissue plasminogen activator: a dose ranging study. Br J Surg 1988;75:1196-200
- Meyerovitz MF, Goldhaber SZ, Reagan K, et al. Recombinant tissue-type plasminogen activator versus urokinase in peripheral arterial and graft occlusions: a randomized trial. Radiology 1990;175:75-8
- Lonsdale RJ, Berridge DC, Earnshaw JJ, et al. Recombinant tissue-type plasminogen activator is superior to streptokinase for local intra-arterial thrombolysis. Br J Surg 1992;79:272-5
- Graor RA, Risius B, Young JR, et al. Thrombolysis of peripheral arterial bypass grafts: surgical thrombectomy compared with thrombolysis. J Vasc Surg 1988;7:347-55
- McNamara TO, Fischer JR. Thrombolysis of peripheral arterial and graft occlusions: improved results using high-dose urokinase. Am J Roentgentol 1985;144:769-75
- Graor RA, Olin JW, Bacharach M. Comparison of t-PA and urokinase for peripheral arterial thrombolysis. J Vasc Med Biol 1993;4:311-4
- Bero CJ, Cardella JF, Reddy K, et al. Recombinant tissue plasminogen activator for the treatment of lower extremity peripheral vascular occlusive disease. J Vasc Interv Radiol 1995;6:571-7
- Hess H, Mietaschk A, von Bilderling P, Neller P. Peripheral arterial occlusions: local low-dose thrombolytic therapy with recombinant tissue-type plasminogen activator (rt-PA). Eur J Endovasc Surg 1996;12:97-104
- Van Breda A, Graor RA, Katzen BT, et al. Relative cost-effectiveness of urokinase versus streptokinase in the treatment of peripheral vascular disease. J Vasc Interv Radiol 1991;2(1):77-87
- Van Breda A, Katzen BT, Deutsch AS. Urokinase versus streptokinase in local thrombolysis. Radiology 1987;165(1):109-11
- Retzios AD, Markland FS Jr. A direct-acting fibrinolytic enzyme from the venom of Agkistrodon contortrix contortrix: effects on various components of the human blood coagulation and fibrinolysis systems. Thromb Res 1988;52(6):541-52
- Retzios AD, Markland FS. Fibrinolytic enzymes from the venoms of Agkistrodon contortrix contortrix and Crotalus basiliscus basiliscus: cleavage site specificity towards the alpha-chain of fibrin. Thromb Res 1994;74(4):355-67
- Toombs CF. Alfimeprase: pharmacology of a novel fibrinolytic metalloproteinase for thrombolysis. Haemostasis 2001;31(3-6):141-7
- Randolph A, Chamberlain SH, Chu HL, et al. Amino acid sequence of fibrolase, a direct-acting fibrinolytic enzyme from Agkistrodon controtrix contortrix venom. Protein Sci 1992;1:590-600
- Markland FS, Friedrichs GS, Pewitt SR, Lucchesi BR. Thrombolytic effects of recombinant fibrolase or APSAC in a canine model of carotid artery thrombosis. Circulation 1994;90(50):2558-6
- Hong TT, Huang J, Lucchesi BR. Effect of thrombolysis on myocardial injury: recombinant tissue plasminogen activator vs. alfimeptrase. Am J Physiol Heart Circ Physiol 2006;290(30):H959-67
- Markland FS, Reddy KN, Guan L. Purification and characterization of a direct-acting fibrinolytic enzyme from southern copperhead venom. In: Pirkle H, Markland FS, editors, Hemostasis and animal venoms. New York: Marcel Dekker; 1988. p. 173-89
- Deitcher SR, Funk WD, Buchanan J, et al. Alfimeprase: a novel recombinant direct-acting fibrinolytic. Expert Opin Biol Ther 2006;6(12):1361-9
- Ouriel K, Cynamon J, Weaver FA, et al. A Phase I trial of alfimeprase for peripheral arterial thrombolysis. J Vasc Interv Radiol 2005;16(8):1075-83
- Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 1997;26:517-38